Real‐world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study
Abstract Azvudine and nirmatrelvir-ritonavir (Paxlovid) were widely used to treat patients with COVID-19 in China during the Omicron wave. However, the efficacy and safety of azvudine versus Paxlovid are poorly established. This study included 40,876 hospitalized patients with COVID-19 from eleven h...
Saved in:
Main Authors: | Haiyu Wang, Guangying Cui, Ming Cheng, Tuerganaili Aji, Guotao Li, Xinjun Hu, Guangming Li, Shixi Zhang, Yanyang Zhang, Linqi Diao, Pan Li, Ling Wang, Yiqiang Yuan, Guowu Qian, Ruiqing Zhang, Xiaoli Jin, Juan Wang, Hong Luo, Donghua Zhang, Mingming Wang, Silin Li, Zhan Song, Mengzhao Yang, Guanyue Su, Ranran Sun, Junbiao Chang, Zujiang Yu, Zhigang Ren |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2025-01-01
|
Series: | Signal Transduction and Targeted Therapy |
Online Access: | https://doi.org/10.1038/s41392-025-02126-w |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and pre-existing diabetes
by: Guanyue Su, et al.
Published: (2025-02-01) -
Effect of nirmatrelvir/ritonavir (Paxlovid) on hospitalization among adults with COVID-19: An electronic health record-based target trial emulation from N3C.
by: Abhishek Bhatia, et al.
Published: (2025-01-01) -
Data mining of adverse drug event signals with Nirmatrelvir/Ritonavir from FAERS.
by: Ji Sun, et al.
Published: (2024-01-01) -
Impact of extended-course oral nirmatrelvir/ritonavir in established Long COVID: a case series
by: Alison K. Cohen, et al.
Published: (2025-01-01) -
The interaction between nirmatrelvir/ritonavir and sirolimus: a case report of a kidney recipient with renal insufficiency and COVID-19
by: Yinhua Gong, et al.
Published: (2025-01-01)